{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:31:39Z","timestamp":1768591899106,"version":"3.49.0"},"reference-count":22,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Cutaneous squamous cell carcinoma (cSCC) is a common non-melanoma skin cancer with low rates of local recurrence or distant metastasis except for tumours with high-risk features, which result in significantly decreased rates of overall survival compared with low-risk lesions. Immune checkpoint inhibitors (ICIs) (cemiplimab and pembrolizumab) represent a promising therapeutic option for cases of unresectable or metastatic disease, but despite their benefit, they pose a risk of immune-related adverse effects. We present the case of a patient with recurrent cSCC on cemiplimab, who developed exocrine pancreatic insufficiency induced by ICI. She presented with symptoms related to malabsorption that improved with pancrelipase but did not exhibit hyperglycaemia, contrary to what is commonly described with ICI-exocrine pancreatic insufficiency (EPI). This case highlights the importance of recognising ICI-EPI as a potential adverse effect in patients with malabsorption while on ICI and to risk-stratify patients with high-risk cSCC for prompt treatment and improved outcomes.<\/jats:p>","DOI":"10.1136\/bcr-2025-267746","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T03:45:13Z","timestamp":1764215113000},"page":"e267746","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Exocrine pancreatic insufficiency in a patient with regionally recurrent cutaneous squamous cell carcinoma undergoing treatment with cemiplimab"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-2476","authenticated-orcid":false,"given":"Maria Fernanda","family":"Albuja Altamirano","sequence":"first","affiliation":[{"name":"Internal Medicine, Lincoln Hospital, New York, New York, USA"},{"name":"Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"O\u2019Loughlin","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed","family":"Drews","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025112619450790000_18.11.e267746.1","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.11S2a170S","article-title":"Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations","volume":"11","author":"Bossi","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"2025112619450790000_18.11.e267746.2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.17709","article-title":"Epidemiology of advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025112619450790000_18.11.e267746.3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2023.1353","article-title":"Validation of the 2022 National Comprehensive Cancer Network Risk Stratification for Cutaneous Squamous Cell Carcinoma","volume":"159","author":"Stevens","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025112619450790000_18.11.e267746.4","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","article-title":"NCCN Guidelines\u00ae Insights: Squamous Cell Skin Cancer, Version 1.2022","volume":"19","author":"Schmults","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025112619450790000_18.11.e267746.5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2021.09.067","article-title":"Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study","volume":"86","author":"Tokez","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025112619450790000_18.11.e267746.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101800","article-title":"Cutaneous Squamous Cell Carcinoma: An Updated Review","volume":"16","author":"Jiang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025112619450790000_18.11.e267746.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025112619450790000_18.11.e267746.8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for Immunotherapy-Refractory\/Ineligible Cutaneous Squamous Cell Carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025112619450790000_18.11.e267746.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733917","article-title":"Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma","volume":"11","author":"Boutros","year":"2021","journal-title":"Front Oncol"},{"key":"2025112619450790000_18.11.e267746.10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.035","article-title":"Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma","volume":"170","author":"Petzold","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025112619450790000_18.11.e267746.11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamaoto.2018.3650","article-title":"Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"145","author":"Harris","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2025112619450790000_18.11.e267746.12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jamadermatol.2022.5508","article-title":"Association of Patient Risk Factors, Tumor Characteristics, and Treatment Modality With Poor Outcomes in Primary Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis","volume":"159","author":"Zakhem","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025112619450790000_18.11.e267746.13","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1007\/s12094-024-03839-0","article-title":"Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis","volume":"27","author":"Kreuz","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"2025112619450790000_18.11.e267746.14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.12041","article-title":"Increased incidence of squamous cell carcinoma of the skin after long\u2010term treatment with azathioprine in patients with auto\u2010immune inflammatory rheumatic diseases","volume":"28","author":"van den Reek","year":"2014","journal-title":"Acad Dermatol Venereol"},{"key":"2025112619450790000_18.11.e267746.15","unstructured":"American Cancer Society . Treating basal and squamous cell skin cancer. Available: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8821.00.pdf"},{"key":"2025112619450790000_18.11.e267746.16","first-page":"421","article-title":"Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs","volume":"21","author":"Heppt","year":"2023","journal-title":"J Deutsche Derma Gesell"},{"key":"2025112619450790000_18.11.e267746.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174312","article-title":"Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre","volume":"15","author":"Koch Hein","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025112619450790000_18.11.e267746.18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025112619450790000_18.11.e267746.19","unstructured":"Libtayo . 3 libtayo (cemiplimab-rwlc) clinical study response rates. 2025. Available: https:\/\/www.libtayohcp.com\/cscc\/efficacy\/response-rates"},{"key":"2025112619450790000_18.11.e267746.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2025112619450790000_18.11.e267746.21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/oncolo\/oyad150","article-title":"Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors","volume":"28","author":"Satish","year":"2023","journal-title":"Oncologist"},{"key":"2025112619450790000_18.11.e267746.22","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1471-P"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-267746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T03:45:16Z","timestamp":1764215116000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-267746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bcr-2025-267746"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-267746","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}